TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04483739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib Lenalidomide Dexamethasone
Description: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib Lenalidomide Dexamethasone
Description: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib Lenalidomide Dexamethasone
Description: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab Carfilzomib Lenalidomide Dexamethasone
Description: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab Carfilzomib Lenalidomide Dexamethasone
Description: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab Carfilzomib Lenalidomide Dexamethasone
Description: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation
Study: NCT01518582

Intervention type: DEVICE
Intervention: Cervical arthroplasty surgery with Granvia-C
Description: Discectomy and Cervical arthroplasty according to standard practice of the surgeon
Study: NCT00931892

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten
Description: 3g

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten
Description: 10g
Study: NCT04385797

Intervention type: OTHER
Intervention: Telephone interview
Description: Sociodemographic data. Clinical data. PMCI/MD quality of life, cognition, depression, technophilia and perceived stress and caregiver quality of life and burden assessments.
Study: NCT02203253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: 100 mg by mouth twice a day on days 1-5 after chemotherapy, cycle 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for thalidomide
Description: Placebo tablet manufactured to mimic Thalidomide 25 mg tablet 100 mg by mouth twice a day on days 1-5 after chemotherapy , cycle 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Palonosetron and Dexamethasone
Description: Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron and Dexamethasone
Description: Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
Study: NCT02584634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Administered by IV once every two weeks in doses of either 5 mg/kg or 10 mg/kg
Study: NCT01603368

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri
Description: Oil drops with Lactobacillus reuteri DSM 17938, 125 million bacteria=0.2 ml per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oil drops without Lactobacillus reuteri
Study: NCT03788876

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular electrical stimulation
Description: The NMES training will be applied once a day (30 minutes of application per session with an increase of one minute every two days and reduction in the OFF time), until the discharge from the ICU. The patient will continue with the application also in the Hospitalization Units of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre until discharge.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional care
Description: Physiotherapy protocol will be performed by HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre physiotherapists twice a day, which will consist of exercises for bronchial hygiene, exercises for pulmonary reexpansion, and passive mobilization exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Description: Physiotherapy protocol will be performed by HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre physiotherapists twice a day, which will consist of exercises for bronchial hygiene, exercises for pulmonary reexpansion, and passive mobilization exercises.
Study: NCT02584634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06463922
Description: Tablets taken orally once every day in doses of either 100mg, 75mg, or 50mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Capsules. Taken orally once or twice every day in doses of either 200mg or 250mg.
Study: NCT05339191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassionate image workshop
Description: Participants attend a workshop through which they will be supported to develop and use their own compassionate image.
Study: NCT03318133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anesthesia
Description: in this study, we plan to make a prospective, multicenter, randomized controlled clinical trial to compare the effects of general anesthesia with endotracheal intubation and ultrasound-guided combined lumbar plexus and sacral plexus block with sedative anesthesia on the prognosis of elderly patients with hip fracture to clarify the clinical value of combined lumbar plexus and sacral plexus block with sedative anesthesia in elderly patients with hip fracture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anesthesia
Description: in this study, we plan to make a prospective, multicenter, randomized controlled clinical trial to compare the effects of general anesthesia with endotracheal intubation and ultrasound-guided combined lumbar plexus and sacral plexus block with sedative anesthesia on the prognosis of elderly patients with hip fracture to clarify the clinical value of combined lumbar plexus and sacral plexus block with sedative anesthesia in elderly patients with hip fracture.
Study: NCT03740191

Intervention type: OTHER
Group type: OTHER
Intervention: EPIC questionnaire
Description: The EPIC questionnaire is used to evaluated the Quality of life of the patients including the sexual function.

Intervention type: RADIATION
Group type: OTHER
Intervention: kV x-ray images
Description: After the applied daily fraction, x-ray imaging will be repeated daily to assess for intra-fraction motion of the prostate.

Intervention type: RADIATION
Group type: OTHER
Intervention: Conebeam CT
Description: For the assessment of interfraction target and organs at risk movement. Conebeam CT as soon as it becomes available will be performed 5 x/week or at each day of proton therapy before treatment application.
Study: NCT04587245

Intervention type: OTHER
Intervention: Online questionnaire and interviews
Description: Online questionnaire, financial statements (one month per quarter in 2020) submitted electronically, interview with professional accounting firm and review of data and exit Interview
Study: NCT03794245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Men-Centered HIV Testing
Description: The intervention involves bringing mobile HIV testing to venues where men congregate, talking to them as a group about HIV testing, and then providing testing at that venue.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linkage to Care for HIV+ Men
Description: Men diagnosed with HIV are accompanied to the clinic and registered there with the help of a community health worker.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic-based HIV Testing
Description: Individuals present to a clinic and request HIV counseling and testing
Study: NCT01674361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bitopertin
Description: Bitopertin once daily orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bitopertin
Description: Bitopertin once daily orally.
Study: NCT03794245

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Referral for HIV+ Men
Description: Individuals diagnosed with HIV are referred to the nearest clinic for treatment of HIV
Study: NCT03900234

Intervention type: OTHER
Intervention: No intervention will be administered
Description: No intervention will be studied. Clinical and ultrasound examinations will be used to find the prevalence of CVD.
Study: NCT00659815

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.
Description: Daily care for contact lenses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.
Description: Daily care for contact lenses
Study: NCT01674361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to bitopertin once daily orally.
Study: NCT03271931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active choice
Description: EHR alert prompting cardiologists to make an active choice to prescribe a statin or not.
Study: NCT01674361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to bitopertin once daily orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to bitopertin once daily orally.
Study: NCT02227615

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mango polyphenolics
Description: Frozen Mango (Keitt) packs provided to subjects.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugary beverage
Description: 15.7g sugar, 3.8g pectin and 0.05g citric acid was added in 100ml of the control beverage.
Study: NCT02231957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational text message reminders

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional text message reminders
Study: NCT02895841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMART app wearable
Description: Patients will be given a wearable such as a Microsoft Band accelerometer to track movement, heart rate, galvanic skin response and sleep, which will be collected in combination with the data from the SMART visual dashboard. Data will be sent to the SMART dashboard as well as stored on the iPad/iPod touch via software from the manufacturer. Participants having a wearable device will receive the education intervention (such as haptic prompted texts that state 'try and walk today', 'have you had enough water today', 'make sure to take deep breaths').
Study: NCT01939106

Intervention type: DEVICE
Group type: OTHER
Intervention: One Piece Drainable Pouch
Study: NCT03271931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive choice
Description: EHR passive alert to cardiologists about prescribing a statin
Study: NCT03551145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acellular collagen matrix
Description: 3D collagen matrix consists of the collagen porcine type I and III

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous free gingival graft
Description: Autogenous graft harvested from the posterior palate
Study: NCT00161304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Enanthate
Description: Testosterone Enanthate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04809727

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical biopsy
Description: 4 quadrant biopsy
Study: NCT01674361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.
Study: NCT02146807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picosecond Laser system
Description: Picosecond Laser System for the Treatment of Unwanted Tattoos
Study: NCT03321552

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous deep vein arterialization
Description: Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LimFlow System
Description: Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
Study: NCT01674361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SSRI
Description: Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.
Study: NCT01504542

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS110 vaccine
Description: 0.5ml to be administered twice weekly for 18 weeks (36 doses)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5ml buffered saline placebo to be administered twice weekly for 18 weeks (36 doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS110 vaccine
Description: 0.5 mls to be dosed twice weekly for 18 weeks (36 doses)
Study: NCT02191995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Study: NCT02950545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric Lenses
Description: 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses
Study: NCT01981122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Description: Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Description: Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Enzalutamide is an androgen receptor inhibitor. It is indicated for the treatment of patients with mCRPC who have previously received docetaxel. The enzalutamide dose used in this study will be 160 mg orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Enzalutamide is an androgen receptor inhibitor. It is indicated for the treatment of patients with mCRPC who have previously received docetaxel. The enzalutamide dose used in this study will be 160 mg orally once daily.
Study: NCT02950545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric Lenses
Description: 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric Lenses
Description: 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric Lenses
Description: 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses
Study: NCT00182663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given PO
Study: NCT04333134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3162
Description: Fluzoparib, also known as SHR3162, is an inhibitor of human PARP
Study: NCT00182663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO
Study: NCT01360164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells
Description: Participants will be given hUC-MSCs transplantation.
Study: NCT02444897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural PCA Ropivacaine
Description: Epidural catheter insertion at T10 level before surgery, the tip of catheter location at T8-9 level.~Total volume: 500ml, 16.7mcg/kg+0.75% Ropivacaine 80ml+N/S

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV PCA Fentanyl+nefopam+Ramosetron
Description: Total volume: 84ml, Fentanyl 1000mcg+nefopam 120mg+Ramosetron 0.3mg Basal infusion: 1ml/hr, Bolus: 0.5ml with a lockout time 15min.
Study: NCT03124602

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red Diamond Disposable Pulse Oximeter Sensor
Description: Noninvasive Pulse Oximeter Sensor
Study: NCT02511743

Intervention type: OTHER
Intervention: physicians
Description: physicians taking care of patients with chronic Hepatitis B Virus infection, without intervention
Study: NCT00959140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CD3+ T cell depletion
Description: The peripheral blood stem cell product is engineered to deliver a dose of 15 to 20 x10\^7 CD3+ cells/kg recipient body weight. Other components of the graft will not be manipulated and the recipient will receive the total number of cells collected with the exception of minimal losses that occur during the process of CD3+ T cell isolation. Following collection, CD3+ T cells will be enumerated and a portion of the product containing 15 to 20 x10\^7 CD 3+ cells/kg will be set aside. The remainder of the product will be depleted of CD3+ T cells.~Following CD3+ T cell depletion, the CD3+ T cell depleted product will then be combined with the unmanipulated product to provide the specified levels of CD3+ T cells/kg recipient body-weight. The graft is infused into the patient on the same day as selected and within 24 hours of donor aphaeresis.
Study: NCT03707184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan
Study: NCT03813121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam intravenous infusion
Description: Participants will receive a single drug infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo intravenous infusion
Description: Participants will receive a single placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine intravenous infusion
Description: Participants will receive a single drug infusion
Study: NCT01522274

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity exercise
Description: Brisk walking on a treadmill for 56 minutes 3x per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Videos
Study: NCT04348630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated heatwave exposure
Description: Older adults are exposed to a 8-hour simulated exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated heatwave exposure
Description: Older adults are exposed to a 8-hour simulated exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated heatwave exposure
Description: Older adults are exposed to a 8-hour simulated exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated heatwave exposure
Description: Older adults are exposed to a 8-hour simulated exposure
Study: NCT01974479

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 redirected NK cells
Description: Haploidentical donor NK cells will be expanded and electroporated over 10 days and infused. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day - 7 , and Fludarabine 25 mg/m2/day will be given on day -6 to day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
Study: NCT03622164

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck)
Description: CTV54 includes only the ipsilateral neck, including levels 2-4 plus levels 1 and/or 5 as clinically indicated.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck)
Description: CTV54 includes the entire surgical bed, including bilateral neck lymphatics at risk of harboring microscopic disease
Study: NCT01809561

Intervention type: PROCEDURE
Intervention: tissue biopsy during surgical treatment
Description: The samples collected will test for histological diagnosis of endometriosis and verification tests will be done to characterize the telomeres array and telomerase levels and other characteristics for genomic instability such as spontaneous aneuploidy.
Study: NCT00468546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MabThera/Rituxan
Description: 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 2
Study: NCT03707184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study: NCT00468546

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3
Study: NCT01832194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox